Merck (MEX:MRK) Cyclically Adjusted FCF per Share: MXN84.08 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MRK Merck & Co Inc MEX:MRK
71 GF Score
Price MXN2,569.00
GF Value MXN2,065.47
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted FCF per Share?

Merck MEX:MRK +1.98% 71 Cyclically Adjusted FCF per Share is MXN84.08 as of Jun. 2026. GuruFocus rates MEX:MRK with a GF Score™ of 71/100 and a GF Value™ of MXN2,065.47 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Merck's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN31.627. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN84.08 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Merck's average Cyclically Adjusted FCF Growth Rate was 7.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 5.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Merck was 15.30% per year. The lowest was -3.70% per year. And the median was 5.30% per year.

As of today (2026-09-03), Merck's current stock price is MXN2569.00. Merck's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN84.08. Merck's Cyclically Adjusted Price-to-FCF of today is 30.55.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 17.07. And the median was 24.07.


Merck  (MEX:MRK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Merck's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=2569.00/84.08
=30.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 17.07. And the median was 24.07.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Merck Cyclically Adjusted FCF per Share Related Terms


Merck Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted FCF per Share Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.26 74.56 64.75 92.60 82.23

Merck Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.10 85.16 82.23 83.10 84.08

MEX:MRK vs ABBV, AMGN, GILD: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted Price-to-FCF falls into.


MEX:MRK
71GF Score
Merck & Co Inc MEX:MRK
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=31.627/333.9520*333.9520
=31.627

Current CPI (Jun. 2026) = 333.9520.

Merck Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 17.781 241.428 24.595
201612 22.890 241.432 31.662
201703 -0.361 243.801 -0.494
201706 19.206 244.955 26.184
201709 -10.728 246.819 -14.515
201712 23.769 246.524 32.199
201803 4.726 249.554 6.324
201806 20.400 251.989 27.035
201809 14.947 252.439 19.773
201812 19.851 251.233 26.387
201903 5.522 254.202 7.254
201906 17.086 256.143 22.276
201909 25.077 256.759 32.616
201912 27.719 256.974 36.022
202003 -2.569 258.115 -3.324
202006 25.485 257.797 33.013
202009 6.337 260.280 8.131
202012 20.158 260.474 25.844
202103 5.704 264.877 7.191
202106 11.787 271.696 14.488
202109 29.392 274.310 35.783
202112 30.937 278.802 37.057
202203 29.643 287.504 34.432
202206 25.132 296.311 28.325
202209 35.419 296.808 39.852
202212 25.105 296.797 28.248
202303 2.346 301.836 2.596
202306 18.494 305.109 20.242
202309 46.626 307.789 50.589
202312 -4.963 306.746 -5.403
202403 14.541 312.332 15.548
202406 34.897 314.175 37.094
202409 65.929 315.301 69.829
202412 20.675 315.605 21.877
202503 9.473 319.799 9.892
202506 18.949 322.561 19.618
202509 50.193 324.800 51.607
202512 13.211 324.054 13.615
202603 21.352 330.213 21.594
202606 31.627 333.952 31.627

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN84.08 mean?
Merck (MEX:MRK) has a Cyclically Adjusted FCF per Share of MXN84.08 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Merck and its competitors.
Is Merck's Cyclically Adjusted FCF per Share too high?
Merck's current Cyclically Adjusted FCF per Share is MXN84.08. Overall, Merck has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Merck's Cyclically Adjusted FCF per Share compare to ABBV and AMGN?
Merck's Cyclically Adjusted FCF per Share of MXN84.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Merck and its competitors. Merck's current Cyclically Adjusted FCF per Share is MXN84.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (MEX:MRK) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN2,065.47, compared to a current price of MXN2,569.00 — trading 24.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN84.08. Merck's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Merck (MEX:MRK), the current Cyclically Adjusted FCF per Share is MXN84.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (MEX:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of MXN2,569.00 is trading 24.4% above its estimated GF Value™ of MXN2,065.47. GuruFocus considers Merck to be Modestly Overvalued.

Key valuation signals for MEX:MRK:

  • Cyclically Adjusted FCF per Share: MXN84.08
  • GF Value™: MXN2,065.47 vs. price of MXN2,569.00 (24.4% above fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the MEX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
71GF Score

Get the complete analysis for MEX:MRK

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,569.00
Price
MXN2,065.47
GF Value